NPM1 and T-cell non-Hodgkin lymphoma: In a more recent work, similar findings were observed when GSK1838705, a small molecule IGF-IR/IR/ALK inhibitor, was utilized to treat a variety of different cancers with high expression of IGF-IR, including NPM-ALK+ T-cell lymphoma [177].